Follow the enGene Therapeutics Inc. share price and the full insider trade history of the company, a publicly traded company based in Canada. Shares are quoted on the CA market, under the oversight of SEDI. Market capitalisation: €119.2m. The latest transaction was reported on 24 July 2026 (00 - Opening Balance-Initial SEDI Report). Among the most active insiders: Richton, Kathleen Patricia. The full history is accessible without an account.
18
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate enGene Therapeutics Inc. Hold (neutral), based on 7 analysts. Average price target: US$3.29.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.